Form 4: Elicio Therapeutics CEO Granted Significant Equity Awards

Elicio Therapeutics CEO Robert Connelly received substantial equity awards, including restricted stock units and stock options, effective February 2, 2026.

Summary

• Robert Connelly, CEO, President, and Director of Elicio Therapeutics, Inc. (ELTX), was granted 73,600 Restricted Stock Units (RSUs) on February 2, 2026.
• These RSUs will vest as to 25% on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, contingent on continued service.
• Each RSU represents the right to receive one share of common stock of the Issuer.
• Connelly also acquired 147,200 stock options with an exercise price of $8.1 per share on February 2, 2026.
• The stock options will vest and become exercisable as to 25% on February 2, 2027, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to continued service.
• The stock options have an expiration date of February 2, 2036.
• Following these transactions, Connelly beneficially owns 120,570 shares of common stock directly and 147,200 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management's interests with long-term shareholder value, without indicating any immediate operational or financial performance changes.

Positives

• The grant of restricted stock units and stock options aligns the interests of CEO Robert Connelly with those of shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for executive remuneration, indicating a commitment to retaining key leadership.

Risks

• The vesting of both RSUs and stock options is subject to Robert Connelly's continued service to Elicio Therapeutics, Inc. through the applicable vesting dates, meaning the awards could be forfeited if service ceases prematurely.

Future Outlook

The equity awards are structured with multi-year vesting schedules, indicating an expectation for Robert Connelly's continued leadership and contribution to the company's long-term strategic goals and performance.

Industry Context

StockSavvy.ai notes that the granting of equity awards, such as restricted stock units and stock options, to executive leadership is a common and widely accepted practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to align management incentives with shareholder value creation over the long term, a critical aspect in industries with lengthy development cycles and significant R&D investments.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the CEO's financial interests with shareholder returns, potentially leading to more focused long-term strategic decisions.
• Employees: The compensation structure for the CEO may set a precedent or influence the broader compensation philosophy within the company.

Next Steps

• The vesting of 25% of the RSUs and stock options on February 2, 2027, followed by subsequent annual/monthly vesting installments over three years.

Key Dates

Keywords

Elicio Therapeutics, ELTX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Robert Connelly